Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
25(38%)
Results Posted
38%(3 trials)
Terminated
2(3%)

Phase Distribution

Ph early_phase_1
3
5%
Ph not_applicable
5
8%
Ph phase_3
5
8%
Ph phase_2
32
49%
Ph phase_1
11
17%

Phase Distribution

14

Early Stage

32

Mid Stage

5

Late Stage

Phase Distribution56 total trials
Early Phase 1First-in-human
3(5.4%)
Phase 1Safety & dosage
11(19.6%)
Phase 2Efficacy & side effects
32(57.1%)
Phase 3Large-scale testing
5(8.9%)
N/ANon-phased studies
5(8.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

25

trials recruiting

Total Trials

65

all time

Status Distribution
Active(34)
Completed(8)
Terminated(2)
Other(21)

Detailed Status

Recruiting23
unknown21
Not yet recruiting9
Completed8
Active, not recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
65
Active
25
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 13 (5.4%)
Phase 111 (19.6%)
Phase 232 (57.1%)
Phase 35 (8.9%)
N/A5 (8.9%)

Trials by Status

active_not_recruiting23%
not_yet_recruiting914%
completed812%
terminated23%
recruiting2335%
unknown2132%

Recent Activity

Clinical Trials (65)

Showing 20 of 65 trialsScroll for more
NCT07007182Phase 2

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Recruiting
NCT07551479Phase 3

SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer

Not Yet Recruiting
NCT06964568Phase 3

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Recruiting
NCT07537985Not Applicable

Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment

Completed
NCT05338775Phase 1

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Active Not Recruiting
NCT07432568Phase 2

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Not Yet Recruiting
NCT04093323Phase 2

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Terminated
NCT06710847Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Active Not Recruiting
NCT07182565Phase 1

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT07072351Phase 1

Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT06841679Phase 2

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT07240194Phase 2

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Recruiting
NCT06496373Early Phase 1

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Recruiting
NCT04681131Phase 2

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Completed
NCT04417465Phase 1

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Completed
NCT03425279Phase 1

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Completed
NCT07154108Phase 1

Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer

Not Yet Recruiting
NCT07142200Phase 2

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Not Yet Recruiting
NCT07100405

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment

Recruiting
NCT06896422Phase 1

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
65